Annual EBITDA
$119.69 M
+$16.62 M+16.12%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $119.69 million, with the most recent change of +$16.62 million (+16.12%) on 31 December 2023. During the last 3 years, it has risen by +$78.30 million (+189.15%). CPRX annual EBITDA is now at all-time high.CPRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$60.36 M
-$3.32 M-5.22%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $60.36 million, with the most recent change of -$3.32 million (-5.22%) on 30 September 2024. Over the past year, it has increased by +$88.98 million (+310.90%). CPRX quarterly EBITDA is now -5.22% below its all-time high of $63.68 million, reached on 30 June 2024.CPRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$211.43 M
+$88.98 M+72.67%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $211.43 million, with the most recent change of +$88.98 million (+72.67%) on 30 September 2024. Over the past year, it has increased by +$111.16 million (+110.85%). CPRX TTM EBITDA is now at all-time high.CPRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +16.1% | +310.9% | +110.8% |
| 3 y3 years | +189.2% | +330.1% | +336.5% |
| 5 y5 years | +439.5% | +333.8% | +2199.7% |
CPRX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +189.2% | -5.2% | +310.9% | at high | +336.5% |
| 5 y | 5 years | at high | +439.5% | -5.2% | +310.9% | at high | +2199.7% |
| alltime | all time | at high | +439.5% | -5.2% | +310.9% | at high | +699.7% |
Catalyst Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $60.36 M(-5.2%) | $211.43 M(+72.7%) |
| June 2024 | - | $63.68 M(+74.2%) | $122.45 M(+7.4%) |
| Mar 2024 | - | $36.56 M(-28.1%) | $114.04 M(-4.7%) |
| Dec 2023 | $119.69 M(+16.1%) | $50.84 M(-277.6%) | $119.69 M(+19.4%) |
| Sept 2023 | - | -$28.62 M(-151.8%) | $100.27 M(-35.1%) |
| June 2023 | - | $55.27 M(+30.9%) | $154.55 M(+20.8%) |
| Mar 2023 | - | $42.21 M(+34.4%) | $127.89 M(+24.1%) |
| Dec 2022 | $103.08 M(+96.0%) | $31.42 M(+22.5%) | $103.08 M(+22.1%) |
| Sept 2022 | - | $25.66 M(-10.3%) | $84.44 M(+16.0%) |
| June 2022 | - | $28.61 M(+64.4%) | $72.82 M(+21.2%) |
| Mar 2022 | - | $17.40 M(+36.2%) | $60.08 M(+14.3%) |
| Dec 2021 | $52.58 M(+27.0%) | $12.78 M(-9.0%) | $52.58 M(+8.5%) |
| Sept 2021 | - | $14.04 M(-11.6%) | $48.44 M(+5.0%) |
| June 2021 | - | $15.87 M(+60.3%) | $46.14 M(+13.8%) |
| Mar 2021 | - | $9.90 M(+14.6%) | $40.55 M(-2.1%) |
| Dec 2020 | $41.40 M(+29.9%) | $8.64 M(-26.4%) | $41.43 M(+1.5%) |
| Sept 2020 | - | $11.73 M(+14.1%) | $40.80 M(-5.1%) |
| June 2020 | - | $10.28 M(-4.6%) | $42.98 M(-1.7%) |
| Mar 2020 | - | $10.78 M(+34.6%) | $43.72 M(+36.5%) |
| Dec 2019 | $31.88 M(-190.4%) | $8.01 M(-42.5%) | $32.03 M(+248.4%) |
| Sept 2019 | - | $13.91 M(+26.2%) | $9.19 M(-171.3%) |
| June 2019 | - | $11.03 M(-1305.8%) | -$12.89 M(-57.4%) |
| Mar 2019 | - | -$914.40 K(-93.8%) | -$30.25 M(-14.2%) |
| Dec 2018 | -$35.26 M(+89.2%) | -$14.83 M(+81.5%) | -$35.26 M(+36.0%) |
| Sept 2018 | - | -$8.17 M(+29.2%) | -$25.93 M(+17.6%) |
| June 2018 | - | -$6.33 M(+6.8%) | -$22.05 M(+10.9%) |
| Mar 2018 | - | -$5.93 M(+7.6%) | -$19.89 M(+6.8%) |
| Dec 2017 | -$18.63 M(-3.1%) | -$5.50 M(+28.2%) | -$18.63 M(+6.9%) |
| Sept 2017 | - | -$4.29 M(+3.0%) | -$17.43 M(+2.3%) |
| June 2017 | - | -$4.17 M(-10.7%) | -$17.04 M(-3.6%) |
| Mar 2017 | - | -$4.67 M(+8.5%) | -$17.68 M(-8.1%) |
| Dec 2016 | -$19.24 M(-5.5%) | -$4.30 M(+10.2%) | -$19.24 M(-8.9%) |
| Sept 2016 | - | -$3.90 M(-18.8%) | -$21.12 M(-5.0%) |
| June 2016 | - | -$4.81 M(-22.8%) | -$22.22 M(-0.4%) |
| Mar 2016 | - | -$6.22 M(+0.6%) | -$22.30 M(+9.5%) |
| Dec 2015 | -$20.36 M | -$6.19 M(+23.6%) | -$20.36 M(+12.2%) |
| Sept 2015 | - | -$5.01 M(+2.4%) | -$18.15 M(+5.2%) |
| June 2015 | - | -$4.89 M(+14.1%) | -$17.25 M(+12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$4.28 M(+7.7%) | -$15.35 M(+5.4%) |
| Dec 2014 | -$14.56 M(+41.6%) | -$3.98 M(-3.1%) | -$14.56 M(+9.6%) |
| Sept 2014 | - | -$4.10 M(+37.5%) | -$13.29 M(+6.9%) |
| June 2014 | - | -$2.98 M(-14.8%) | -$12.43 M(+2.8%) |
| Mar 2014 | - | -$3.50 M(+29.7%) | -$12.09 M(+17.5%) |
| Dec 2013 | -$10.29 M(+97.5%) | -$2.70 M(-16.6%) | -$10.29 M(+13.2%) |
| Sept 2013 | - | -$3.24 M(+22.4%) | -$9.09 M(+27.5%) |
| June 2013 | - | -$2.65 M(+55.7%) | -$7.13 M(+28.5%) |
| Mar 2013 | - | -$1.70 M(+13.1%) | -$5.55 M(+6.5%) |
| Dec 2012 | -$5.21 M(-13.7%) | -$1.50 M(+17.3%) | -$5.21 M(-9.1%) |
| Sept 2012 | - | -$1.28 M(+20.3%) | -$5.73 M(+2.8%) |
| June 2012 | - | -$1.06 M(-21.8%) | -$5.58 M(-5.3%) |
| Mar 2012 | - | -$1.36 M(-32.8%) | -$5.89 M(-2.5%) |
| Dec 2011 | -$6.04 M(+51.0%) | -$2.03 M(+80.4%) | -$6.04 M(+27.5%) |
| Sept 2011 | - | -$1.12 M(-18.4%) | -$4.74 M(+4.9%) |
| June 2011 | - | -$1.38 M(-9.0%) | -$4.52 M(+1.1%) |
| Mar 2011 | - | -$1.51 M(+108.5%) | -$4.47 M(+11.7%) |
| Dec 2010 | -$4.00 M(-44.8%) | -$725.70 K(-19.6%) | -$4.00 M(-9.9%) |
| Sept 2010 | - | -$902.20 K(-32.0%) | -$4.44 M(-7.9%) |
| June 2010 | - | -$1.33 M(+27.1%) | -$4.82 M(-8.3%) |
| Mar 2010 | - | -$1.04 M(-10.2%) | -$5.25 M(-27.5%) |
| Dec 2009 | -$7.25 M(-33.3%) | -$1.16 M(-9.5%) | -$7.25 M(-26.6%) |
| Sept 2009 | - | -$1.28 M(-27.0%) | -$9.87 M(-14.1%) |
| June 2009 | - | -$1.76 M(-42.0%) | -$11.49 M(-5.7%) |
| Mar 2009 | - | -$3.04 M(-19.7%) | -$12.18 M(+12.2%) |
| Dec 2008 | -$10.86 M(+116.7%) | -$3.78 M(+30.2%) | -$10.86 M(+32.2%) |
| Sept 2008 | - | -$2.91 M(+18.4%) | -$8.21 M(+31.3%) |
| June 2008 | - | -$2.46 M(+43.1%) | -$6.25 M(+19.5%) |
| Mar 2008 | - | -$1.72 M(+51.2%) | -$5.23 M(+4.4%) |
| Dec 2007 | -$5.01 M(+73.0%) | -$1.13 M(+19.8%) | -$5.01 M(+5.3%) |
| Sept 2007 | - | -$947.00 K(-34.0%) | -$4.76 M(-7.6%) |
| June 2007 | - | -$1.43 M(-4.1%) | -$5.15 M(+26.4%) |
| Mar 2007 | - | -$1.50 M(+69.1%) | -$4.08 M(+57.9%) |
| Dec 2006 | -$2.90 M(+59.1%) | -$884.40 K(-34.0%) | -$2.58 M(+52.1%) |
| Sept 2006 | - | -$1.34 M(+275.4%) | -$1.70 M(+375.4%) |
| June 2006 | - | -$357.00 K | -$357.00 K |
| Dec 2005 | -$1.82 M(+235.6%) | - | - |
| Dec 2004 | -$542.60 K(+112.0%) | - | - |
| Dec 2002 | -$255.90 K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Catalyst Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM EBITDA year-on-year change?
What is Catalyst Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CPRX is $119.69 M
What is the all time high annual EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $119.69 M
What is Catalyst Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, CPRX annual earnings before interest, taxes, depreciation & amortization has changed by +$16.62 M (+16.12%)
What is Catalyst Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CPRX is $60.36 M
What is the all time high quarterly EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $63.68 M
What is Catalyst Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, CPRX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$88.98 M (+310.90%)
What is Catalyst Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CPRX is $211.43 M
What is the all time high TTM EBITDA for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $211.43 M
What is Catalyst Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, CPRX TTM earnings before interest, taxes, depreciation & amortization has changed by +$111.16 M (+110.85%)